Tyler Van Buren
Stock Analyst at TD Cowen
(2.56)
# 2,340
Out of 5,072 analysts
59
Total ratings
50%
Success rate
1.86%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Buy | $50 → $15 | $9.48 | +58.23% | 3 | Nov 5, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | n/a | $33.82 | - | 1 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $30 → $40 | $36.26 | +10.31% | 2 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $95 | $71.72 | +32.46% | 2 | Oct 30, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $115 → $125 | $127.51 | -1.97% | 6 | Oct 23, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | n/a | $35.88 | - | 1 | Jul 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | n/a | $44.84 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $17.50 | - | 2 | Dec 12, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $19.00 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $30.46 | - | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $70 → $60 | $25.01 | +139.90% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $3.58 | - | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $7.60 | - | 1 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,030 → $1,200 | $784.61 | +52.94% | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $21.39 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $41.45 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $53.30 | -43.71% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $29.75 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $73.25 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $70.39 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.10 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $40.13 | +74.43% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.44 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.42 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $22.03 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $15.08 | +1,392.04% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $9.86 | +8,774.24% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $17.20 | +132.56% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $19.96 | +50.30% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.58 | +3,064.56% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $3.34 | +798.20% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $4.16 | +4,707.69% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.63 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $26.32 | - | 1 | Aug 4, 2017 |
Biohaven
Nov 5, 2025
Maintains: Buy
Price Target: $50 → $15
Current: $9.48
Upside: +58.23%
MBX Biosciences
Nov 4, 2025
Initiates: Buy
Price Target: n/a
Current: $33.82
Upside: -
Travere Therapeutics
Oct 31, 2025
Maintains: Buy
Price Target: $30 → $40
Current: $36.26
Upside: +10.31%
BridgeBio Pharma
Oct 30, 2025
Maintains: Buy
Price Target: $60 → $95
Current: $71.72
Upside: +32.46%
Gilead Sciences
Oct 23, 2025
Maintains: Buy
Price Target: $115 → $125
Current: $127.51
Upside: -1.97%
IDEAYA Biosciences
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $35.88
Upside: -
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $44.84
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $17.50
Upside: -
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $19.00
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $30.46
Upside: -
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $25.01
Upside: +139.90%
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $3.58
Upside: -
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $7.60
Upside: -
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $784.61
Upside: +52.94%
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $21.39
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $41.45
Upside: -
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $53.30
Upside: -43.71%
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $29.75
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $73.25
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $70.39
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.10
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $40.13
Upside: +74.43%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.44
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $12.42
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $22.03
Upside: -
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $15.08
Upside: +1,392.04%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $9.86
Upside: +8,774.24%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $17.20
Upside: +132.56%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $19.96
Upside: +50.30%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.58
Upside: +3,064.56%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $3.34
Upside: +798.20%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $4.16
Upside: +4,707.69%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $9.63
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $26.32
Upside: -